Endocrine pancreatic insufficiency (new onset) ‐ long‐term · participants with painful obstructive chronic pancreatitis
Endoscopy showed no clear difference in endocrine pancreatic insufficiency (new onset) ‐ long‐term compared with surgery (low certainty).
1 finding from 1 review
Exocrine pancreatic insufficiency (new onset) · participants with painful obstructive chronic pancreatitis
Endoscopy showed no clear difference in exocrine pancreatic insufficiency (new onset) ‐ long‐term compared with surgery (moderate certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · participants with painful obstructive chronic pancreatitis
Surgery may leads to higher pain relief compared with conservative treatment (low certainty).
1 finding from 1 review
Major complications ‐ not reported · participants with painful obstructive chronic pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment failure Feeding interruption, blocking or leakage of the tube, non‐adherence · adult patients with swallowing disturbances
Percutaneous endoscopic gastrostomy may leads to lower treatment failure Feeding interruption, blocking or leakage of the… compared with nasogastric tube feeding (low certainty).
1 finding from 1 review
Mortality irrespective of · adult patients with swallowing disturbances
It is very uncertain whether percutaneous endoscopic gastrostomy changes mortality irrespective of compared with nasogastric tube feeding (very low certainty).
1 finding from 1 review
Pneumonia · adult patients with swallowing disturbances
Percutaneous endoscopic gastrostomy showed no clear difference in pneumonia irrespective of compared with nasogastric tube feeding (low certainty).
1 finding from 1 review
Adverse events irrespective of · adult patients with swallowing disturbances
Percutaneous endoscopic gastrostomy showed no clear difference in adverse events irrespective of compared with nasogastric tube feeding (moderate certainty).
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Interferon‐B‐1a showed no clear difference in improved IBDQ at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
IBDQ at week 8 · people with active UC
1 finding from 1 review
QoL · people with active UC
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
Improved IBDQ at week 52 · people with active UC
Vedolizumab probably leads to higher improved IBDQ at week 6 compared with placebo (moderate certainty).
2 findings from 1 review
SF‐36 PCS at week 6 · people with active UC
1 finding from 1 review
Improved SF‐36 MCS at week 8 · people with active UC
1 finding from 1 review
Health‐related quality of life Multiple different outcome measures used EQ‐5D and EQ‐5D VAS (9 and 26 weeks) (Batterham 2014) SF‐36 PCS and MCS (8 and 26 weeks) (Elliott 2011) · people with active UC
1 finding from 1 review
SF‐36 MCS at week 52 · people with active UC
1 finding from 1 review
IBDQ at weeks 6 or 8 · people with active UC
TNF‐alpha antagonists leads to higher improved IBDQ at weeks 6 or 8 compared with placebo (high certainty).
2 findings from 1 review
QoL · people with active UC
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Infliximab leads to higher improved IBDQ at week 8 compared with placebo (high certainty).
1 finding from 1 review